Abstract
Background and Objectives : Acute kidney injury (AKI) is a common complication in patients with coronavirus disease 2019 (COVID-19). We investigated the values of procalcitonin (PCT) and presepsin (PSS) for predicting AKI and 30-day hospital mortality in patients with COVID-19. Materials and Methods : We retrospectively evaluated 151 patients with COVID-19 who were admitted to the hospital via the emergency department. The diagnosis of AKI was based on the Kidney Disease: Improving Global Outcomes clinical practice guidelines. Results : The median patient age was 77 years, and 86 patients (57%) were male. Fifty-six patients (37.1%) developed AKI, and 19 patients (12.6%) died within 30 days of hospital admission. PCT and PSS levels were significantly higher in patients with AKI and non-survivors. The cutoff values of PCT levels for predicting AKI and mortality were 2.26 ng/mL (sensitivity, 64.3%; specificity, 89.5%) and 2.67 ng/mL (sensitivity, 68.4%; specificity, 77.3%), respectively. The cutoff values of PSS levels for predicting AKI and mortality were 572 pg/mL (sensitivity, 66.0%; specificity, 69.1%) and 865 pg/mL (sensitivity, 84.6%; specificity, 76.0%), respectively. Conclusion : PCT and PSS are valuable biomarkers for predicting AKI and 30-day hospital mortality in patients with COVID-19.
Keywords: COVID-19; acute kidney injury; mortality; presepsin; procalcitonin.
【저자키워드】 COVID-19, Mortality, Acute kidney injury, Presepsin, procalcitonin., 【초록키워드】 coronavirus disease, Coronavirus disease 2019, Biomarker, hospital, Diagnosis, procalcitonin, Acute kidney injury, emergency department, Kidney injury, sensitivity, specificity, AKI, male, Patient, Kidney disease, age, Hospital admission, Clinical practice, patient age, Non-survivors, material, cutoff value, objective, PCT, Result, died, investigated, evaluated, median, significantly higher, acute kidney, Improving, patients with AKI, patients with COVID-19, PSS, 【제목키워드】 value, with COVID-19,